Use of progression-free survival as a valid endpoint in phase II cancer clinical trials Maurie Markman Editor’s Commentary 26 April 2007 Pages: 159 - 160
Web alert David S. Hong MD Division of Medicine, Phase I Program and Gl Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. E-mail: dshong@mdanderson.org EditorialNotes 26 April 2007 Pages: 161 - 161
Recent advances in therapy for gastrointestinal stromal tumors Robert G. Maki OriginalPaper 26 April 2007 Pages: 165 - 169
Pancreatic cancer: An update Hedy Lee KindlerKathryn Bylow OriginalPaper 26 April 2007 Pages: 170 - 176
New developments in the treatment of gastrointestinal neuroendocrine tumors Matthew H. Kulke OriginalPaper 26 April 2007 Pages: 177 - 183
Combined-modality therapy for esophageal and gastroesophageal junction cancers Harry H. YoonMichael K. Gibson OriginalPaper 26 April 2007 Pages: 184 - 192
Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases Timothy M. PawlikMichael A. Choti OriginalPaper 26 April 2007 Pages: 193 - 201
Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer Mark A. JenkinsMelissa C. SoutheyJohn L. Hopper OriginalPaper 26 April 2007 Pages: 202 - 207
Clinical trials in metastatic hormone-refractory prostate cancer: Improving docetaxel therapy by targeting bone-related growth factors Daniel P. Petrylak Clinical Trials Report 26 April 2007 Pages: 211 - 212
The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer John P. Stein OriginalPaper 26 April 2007 Pages: 213 - 221
The role of high-intensity focused ultrasound in prostate cancer John H. LynchStacy Loeb OriginalPaper 26 April 2007 Pages: 222 - 225
Immunotherapy for prostate cancer Lawrence FongEric J. Small OriginalPaper 26 April 2007 Pages: 226 - 233